Last update Oct. 30, 2024

Fexinidazole

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Fexinidazole is a 5-nitroimidazole derivative with properties similar to those of metronidazole. It is used in the treatment of first and second stage African trypanosomiasis due to Trypanosoma brucei gambiense infection (Gambian or West African sleeping sickness). Fexinidazole does not appear to be effective against American trypanosomiasis or Chagas disease (Pinazo 2024). Oral administration once daily for 10 days.

At the date of the last update, we found no published data on its excretion in breast milk.

Its high percentage of protein binding, but especially its very high volume of distribution, would make excretion in breast milk difficult.

Authorized use in pediatrics from 6 years of age or 20 kg of weight.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Fexinidazole in other languages or writings:

Group

Fexinidazole belongs to this group or family:

Pharmacokinetics

Variable Value Unit
Molecular weight 279 daltons
Protein Binding 98 (Metab: 41 - 57) %
VD 46 ± 17 l/Kg
Tmax 4 - 6 hours
T½ 15 ± 6 (Metab: 23 ± 4) hours

References

  1. Pinazo MJ, Forsyth C, Losada I, Esteban ET, García-Rodríguez M, Villegas ML, Molina I, Crespillo-Andújar C, Gállego M, Ballart C, Ramirez JC, Aden T, Hoerauf A, Pfarr K, Vaillant M, Marques T, Fernandes J, Blum B, Ribeiro I, Sosa-Estani S, Barreira F, Gascón J; et al. Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2024 Apr;24(4):395-403. Abstract
  2. Sanofi W. Fexinidazole tablets. Drug DSummary. 2022 Full text (link to original source) Full text (in our servers)
  3. FDA. Fexinidazole tablets. Drug Summary 2021 Full text (link to original source) Full text (in our servers)
  4. Deeks ED. Fexinidazole: First Global Approval. Drugs. 2019 Feb;79(2):215-220. Abstract
  5. - Fexinidazole. 2023 Jul 18. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Abstract Full text (link to original source)

Total visits

51

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM